Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discover effective wealth growth strategies for beginners that pave the way to financial success. Start learning and investing wisely now.
23,833 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
AI demand is broadening from chipmakers to the hardware backbone that powers deployments, a shift that could lift inf...
NVIDIA stakes its AI dominance on data center hardware while Palantir expands software driven growth, setting up a hi...
A strong earnings beat and improving fundamentals pushed Barrick's stock higher. This article breaks down the factors...
Lucid stock sits near $7, tempting bargain hunters. This article breaks down the real risks, the potential catalysts,...
AI-driven tech stocks swing in early 2026 as valuations recalibrate. Analysts say a consumer staples ETF can help hed...
European leaders weigh price caps on essentials to curb inflation, a move that has CEOs warning of market distortions...
An Australian-born fast-casual chain that once eyed a nationwide U.S. footprint has abruptly shut down all U.S. locat...
A late-stage planning window lets a 67-year-old solo 401(k) holder convert pre-tax balances to Roth, tapping substant...
ServiceNow climbs as investors chase AI-driven growth in enterprise software, with Dell's recent results helping lift...
Income-focused investors are turning to a small group of high-yield energy names that offer cash-flow visibility and ...
Broadcom kept its AI growth outlook steady for the next quarter, but the stock dropped sharply as investors priced in...